Birgit Pruess, NDSU professor of microbiological sciences, has written a review article about drugs being tested to fight COVID-19 and its infection agent, SARS C0V-2.
“Current status of drug development against SARS CoV-2 infections” was published Aug. 17 in Medical Research Archives, a KEI journal.
According to the World Health Organization, as of June 24, there were more than 9 million confirmed cases and nearly 475,000 deaths worldwide.
Pruess’ review focused on drugs against the virus itself, including camostat mesylate, recombinant human angiotension converting enzyme 2, controversial Hydroxychloroquine, remdesivir, faripiravir, tenofovir lopinavir/ritonavir and ivermectin.
Many of the presented drugs have previously been used for a different disease and are currently being trialed against SARS CoV-2.
“There is hope. At least three of the reviewed drugs look promising, though further research is required to assess efficacy,” Pruess said.
Pruess earned her doctorate at Ruhr-Universität Bochum Germany. Her honors include the 2006 Larson/Yaggie Excellence in Research Award and the 2010 William J. and Angelyn A. Austin Advising Award.
As a student-focused, land-grant, research university, we serve our citizens.
